Matching Placebo for Venetoclax
Sponsors
AbbVie Deutschland GmbH & Co. KG
Conditions
Acute Myeloid Leukemia
Phase 3
A Randomized, Double-Blind, Placebo Controlled Study of Venetoclax Co-Administered with Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naïve Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
CompletedCTIS2024-513630-37-00
Start: 2017-10-24End: 2025-06-23Target: 1Updated: 2024-07-01
A Randomized, Double-blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Naïve Subjects with Acute Myeloid Leukemia who are Ineligible for Standard Induction Therapy, Incorporating Extension Period - Continued Access for Venetoclax. (VIALE-A)
CompletedCTIS2024-513631-25-00
Start: 2017-08-17End: 2025-09-15Target: 83Updated: 2025-09-18